BACKGROUND: The surface epithelial glycoprotein MUC1 becomes overexpressed and hypoglycosylated in adenocarcinomas; similar changes occur during nonmalignant inflammatory events. Antibodies developed against tumor-like MUC1 in response to such events could be one way through which ovarian cancer risk factors operate. METHODS: We evaluated the association between anti-MUC1 antibodies and risk of ovarian cancer in a prospective nested case-control study in the Nurses' Health Studies. We used an ELISA to measure plasma anti-MUC1 antibodies in 117 ovarian cancer cases collected at least 3 years before diagnosis and 339 matched controls. RESULTS: In controls, younger women (P-trend = 0.03), those with a tubal ligation (P = 0.03), and those with fewer ovulatory cycles (P-trend = 0.04) had higher antibody levels. In cases, women with late-stage disease (P = 0.04) and those whose specimen was >11 years remote from diagnosis (P = 0.01) had higher antibody levels. Overall, increasing anti-MUC1 antibody levels were associated with a nonsignificant trend for lower risk for ovarian cancer, but there was highly significant heterogeneity by age (P-heterogeneity = 0.005). In women <64 years, the antibody level in quartiles 2 to 4 versus quartile 1 were associated with reduced risk (relative risk = 0.53; 95% confidence interval, 0.31-0.93; P-trend = 0.03), whereas in women > or = 64 years, the corresponding relative risk was 2.11 (95% confidence interval, 0.73-6.04); P-trend = 0.05). CONCLUSION: Anti-MUC1 antibodies evaluated several years before diagnosis may be associated with lower risk of subsequent ovarian cancer in women <64 years old at assessment. IMPACT: Key elements of an "immune model" to explain ovarian cancer risk factors are confirmed and should be evaluated in larger prospective studies. Copyright 2010 AACR.
BACKGROUND: The surface epithelial glycoprotein MUC1 becomes overexpressed and hypoglycosylated in adenocarcinomas; similar changes occur during nonmalignant inflammatory events. Antibodies developed against tumor-like MUC1 in response to such events could be one way through which ovarian cancer risk factors operate. METHODS: We evaluated the association between anti-MUC1 antibodies and risk of ovarian cancer in a prospective nested case-control study in the Nurses' Health Studies. We used an ELISA to measure plasma anti-MUC1 antibodies in 117 ovarian cancer cases collected at least 3 years before diagnosis and 339 matched controls. RESULTS: In controls, younger women (P-trend = 0.03), those with a tubal ligation (P = 0.03), and those with fewer ovulatory cycles (P-trend = 0.04) had higher antibody levels. In cases, women with late-stage disease (P = 0.04) and those whose specimen was >11 years remote from diagnosis (P = 0.01) had higher antibody levels. Overall, increasing anti-MUC1 antibody levels were associated with a nonsignificant trend for lower risk for ovarian cancer, but there was highly significant heterogeneity by age (P-heterogeneity = 0.005). In women <64 years, the antibody level in quartiles 2 to 4 versus quartile 1 were associated with reduced risk (relative risk = 0.53; 95% confidence interval, 0.31-0.93; P-trend = 0.03), whereas in women > or = 64 years, the corresponding relative risk was 2.11 (95% confidence interval, 0.73-6.04); P-trend = 0.05). CONCLUSION: Anti-MUC1 antibodies evaluated several years before diagnosis may be associated with lower risk of subsequent ovarian cancer in women <64 years old at assessment. IMPACT: Key elements of an "immune model" to explain ovarian cancer risk factors are confirmed and should be evaluated in larger prospective studies. Copyright 2010 AACR.
Authors: D M Gertig; D J Hunter; D W Cramer; G A Colditz; F E Speizer; W C Willett; S E Hankinson Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: G G Bon; P Kenemans; A A Verstraeten; S Go; P A Philipi; G J van Kamp; H P van Geijn; J M van Vugt Journal: Fetal Diagn Ther Date: 2001 May-Jun Impact factor: 2.587
Authors: Anda M Vlad; Stefan Muller; Mare Cudic; Hans Paulsen; Laszlo Otvos; Franz-Georg Hanisch; Olivera J Finn Journal: J Exp Med Date: 2002-12-02 Impact factor: 14.307
Authors: Ana Babic; Elizabeth M Poole; Kathryn L Terry; Daniel W Cramer; Ricardo P Teles; Shelley S Tworoger Journal: Cancer Causes Control Date: 2015-04-03 Impact factor: 2.506
Authors: J P Pandey; E Kistner-Griffin; A M Namboodiri; M Iwasaki; Y Kasuga; G S Hamada; S Tsugane Journal: Clin Exp Immunol Date: 2014-10 Impact factor: 4.330
Authors: Megan S Rice; Megan A Murphy; Allison F Vitonis; Daniel W Cramer; Linda J Titus; Shelley S Tworoger; Kathryn L Terry Journal: Int J Cancer Date: 2013-07-09 Impact factor: 7.396
Authors: Camille Jacqueline; Amanda Lee; Nolan Frey; Jonathan S Minden; Olivera J Finn Journal: Cancer Immunol Res Date: 2020-05-28 Impact factor: 11.151
Authors: Kristina A Williams; S Intidhar Labidi-Galy; Kathryn L Terry; Allison F Vitonis; William R Welch; Annekathryn Goodman; Daniel W Cramer Journal: Gynecol Oncol Date: 2014-01-23 Impact factor: 5.482